Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L23a pseudogene 85 (RPL23AP85) is a processed, non-functional pseudogene located on human chromosome 8 (Ensembl: ENSG00000224980; NCBI Gene: 100419650).[6][8][9][10] It is part of a large family of ribosomal protein L23a pseudogenes dispersed throughout the human genome, all derived from the functional ribosomal protein L23a gene (RPL23A) through retrotransposition.[3][6][1] Pseudogenes like RPL23AP85 generally lack protein-coding ability and are not known to produce functional proteins or have direct cellular roles. There is currently no evidence that RPL23AP85 itself plays a significant role in human disease, biology, or therapeutic modulation.\n\nEssential context and supporting details:\n- RPL23AP85 is clearly annotated as a "processed pseudogene" by major databases (GeneCards, Ensembl, NCBI), meaning it does not code for an active protein and is not considered a druggable or therapeutic target.[1][6][8][9]\n- Pseudogenes related to ribosomal protein L23a are common in the genome, but only the functional gene (RPL23A) encodes the protein component of the ribosome, with established roles in protein synthesis and cell growth.[3][5][7][13]\n- While some pseudogenes (such as RPL23AP53) have been investigated for potential regulatory or disease association roles, there is no direct evidence for any such function for RPL23AP85 at this time.[4]\n- Drug interactions, mechanisms of action, biomarker roles, or safety concerns are not relevant for this pseudogene, as it does not encode a functional RNA or protein product.\n\nIn summary, RPL23AP85 is a non-coding processed pseudogene, is not considered a therapeutic target, has no established alias beyond its systematic symbol, and falls within the "other" molecular and functional classification relevant only to pseudogenes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L23a pseudogene 85 (RPL23AP85).